Keyphrases
Pediatric
63%
Pediatric Patients
55%
Acute Lymphoblastic Leukemia
54%
Acute Myeloid Leukemia
52%
Pediatric Leukemia
47%
Netherlands
41%
Pharmacokinetics
30%
Dutch
28%
Leukemia
25%
KMT2A
25%
Improved Survival
21%
Population Pharmacokinetics
20%
Newly Diagnosed
19%
Relapsed or Refractory
19%
Pediatric Oncology
18%
Children with Cancer
18%
Gemtuzumab Ozogamicin
18%
Overall Survival
17%
Confidence Interval
17%
Leukemia Patients
17%
Young Adolescents
17%
Older Adults
16%
Phase II Study
16%
Pediatric Acute Lymphoblastic Leukemia
16%
Neuroblastoma
14%
Preadolescent children
14%
High-risk Neuroblastoma
14%
Chemotherapy
13%
Minimal Residual Disease
13%
Precision Oncology
13%
Relapsed or Refractory Acute Myeloid Leukemia
13%
Down Syndrome
12%
Hematopoietic Stem Cell Transplantation
12%
Event-free Survival
11%
Pediatric Cancer
11%
Average Annual Percentage Change
11%
Acute Leukemia
11%
T Cells
11%
T-cell Acute Lymphoblastic Leukemia (T-ALL)
11%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
11%
Hematopoietic Stem Cells
11%
Oncology
10%
CD22
10%
Bone Marrow
10%
Chronic Myeloid Leukemia
10%
Population-based Study
10%
5-year Survival
10%
Clinical Outcomes
10%
Cancer-related Fatigue
9%
Aprepitant
9%
Neonate
9%
RNA Sequencing (RNA-seq)
9%
Phase II Trial
9%
Childhood Acute Lymphoblastic Leukemia
9%
High Risk
9%
Treatment Response
9%
BCP-ALL
8%
Menin Inhibitors
8%
Improved Outcomes
8%
Cancer Registry
8%
Hodgkin Lymphoma
8%
Clinically Significant
8%
Pediatric AML
7%
Dose-limiting Toxicity
7%
Chimeric Antigen Receptor T-cell Therapy
7%
Wilms Tumor
7%
Targeted Treatment
7%
Sleep Problems
7%
Paediatric Strategy Forum
7%
Dinutuximab
7%
Non-Hodgkin Lymphoma
7%
Solid Tumors
7%
Working Diagnosis
7%
Recommended Phase 2 Dose
7%
Frankfurt
7%
Berlin
7%
Incidence Trends
7%
European Medicines Agency
7%
Clinical Trials
7%
Fusion Gene
7%
Myelodysplastic Syndrome
7%
Clinical Practice
7%
Liquid Chromatography-tandem Mass Spectrometry (LC-MS/MS)
6%
Complete Remission
6%
Risk Factors
6%
Innovative Therapies
6%
Targeted Therapy
6%
Survival Rate
6%
Young Cancer Patients
6%
DOT1L Inhibitor
6%
Genome Analysis
6%
Azacitidine
6%
Clofarabine
6%
Sleep-wake Rhythm
6%
Nilotinib
6%
Treatment Effect
6%
Personalized Therapy
6%
Differentiated Thyroid Cancer
6%
Multidimensional Analysis
6%
Cancer Program
6%
Medicine and Dentistry
Pediatrics
100%
Acute Lymphoblastic Leukemia
55%
Acute Myeloid Leukemia
48%
Adolescence
40%
Pediatric Acute Myeloid Leukemia
36%
Ganglioneuroblastoma
34%
Malignant Neoplasm
33%
Pediatrics Patient
32%
Neoplasm
26%
Overall Survival
23%
Childhood Cancer
22%
Leukemia
19%
Disease
19%
Immunotherapy
19%
Oncology
18%
Targeted Therapy
15%
Acute Myelogenous Leukemia
15%
Diseases
15%
Personalized Medicine
14%
Inotuzumab Ozogamicin
14%
Cancer
12%
Pediatric Cancer
12%
Down Syndrome
11%
Minimal Residual Disease
11%
Acute Leukemia
11%
Leukemia in Children
10%
Hematopoietic Cell
10%
Clinical Trial
10%
T Cell
10%
Dexamethasone
9%
Maintenance Therapy
9%
Hodgkin's Lymphoma
8%
Event Free Survival
8%
Somatics
8%
Cancer Registry
8%
Treatment Response
8%
Hematopoietic Stem Cell Transplantation
8%
Chemotherapy
7%
Solid Malignant Neoplasm
7%
Hazard Ratio
7%
Phase II Trials
7%
Survival Rate
7%
Progression Free Survival
7%
Kidney Tumour
7%
Carcinogenesis
7%
Medicine
7%
Randomized Controlled Trial
6%
Wilms' Tumor
6%
Cancer-Related Fatigue
6%
Sleep Waking Cycle
6%
Retrospective Study
6%
Topotecan
6%
Liquid Biopsy
6%
Temozolomide
6%
Precision Oncology
6%
B Cell
6%
Arm
5%
High Throughput Screening
5%
Leukemia Cell
5%
Transcriptomics
5%
Central Nervous System Tumor
5%
Anaplastic Lymphoma Kinase
5%
Experimental Therapy
5%
Non-Hodgkin Lymphoma
5%